These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35898553)
1. Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Wang RL; Liu P; Chen XF; Yao X; Liao XP; Liu YH; Sun J; Zhou YF Front Vet Sci; 2022; 9():945632. PubMed ID: 35898553 [TBL] [Abstract][Full Text] [Related]
2. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets. Zhou YF; Bu MX; Liu P; Sun J; Liu YH; Liao XP BMC Vet Res; 2020 Mar; 16(1):81. PubMed ID: 32138735 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for Zhou YF; Peng HM; Bu MX; Liu YH; Sun J; Liao XP Front Pharmacol; 2017; 8():684. PubMed ID: 29033841 [TBL] [Abstract][Full Text] [Related]
4. Comparison of PK/PD Targets and Cutoff Values for Danofloxacin Against Zhou YF; Sun Z; Wang RL; Li JG; Niu CY; Li XA; Feng YY; Sun J; Liu YH; Liao XP Front Vet Sci; 2022; 9():811967. PubMed ID: 35187143 [TBL] [Abstract][Full Text] [Related]
5. PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against Huang A; Mao F; Huang L; Xie S; Pan Y; Qu W; Cheng G; Liu Z; Yuan Z; Peng D; Hao H Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203885 [No Abstract] [Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs. Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326 [TBL] [Abstract][Full Text] [Related]
7. Determination of Susceptibility Breakpoint for Cefquinome against Mi K; Li M; Sun L; Hou Y; Zhou K; Hao H; Pan Y; Liu Z; Xie C; Huang L Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439008 [No Abstract] [Full Text] [Related]
8. Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against Somogyi Z; Mag P; Kovács D; Kerek Á; Szabó P; Makrai L; Jerzsele Á Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057005 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of Gamithromycin Treatment of Yang Q; Liu X; Zhang C; Yong K; Clifton AC; Ding H; Liu Y Front Pharmacol; 2019; 10():1090. PubMed ID: 31680940 [TBL] [Abstract][Full Text] [Related]
10. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264 [TBL] [Abstract][Full Text] [Related]
11. PK-PD Integration Modeling and Cutoff Value of Florfenicol against Lei Z; Liu Q; Yang S; Yang B; Khaliq H; Li K; Ahmed S; Sajid A; Zhang B; Chen P; Qiu Y; Cao J; He Q Front Pharmacol; 2018; 9():2. PubMed ID: 29387013 [TBL] [Abstract][Full Text] [Related]
12. Xiao X; Lan W; Zhao Y; Li R; Liu Y; Liu J; Wang Z Front Microbiol; 2020; 11():616685. PubMed ID: 33505384 [No Abstract] [Full Text] [Related]
13. Increased Antimicrobial Activity of Colistin in Combination With Gamithromycin Against Li Y; Xie M; Zhou J; Lin H; Xiao T; Wu L; Ding H; Fang B Front Microbiol; 2020; 11():511356. PubMed ID: 33072002 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle. DeDonder KD; Apley MD; Li M; Gehring R; Harhay DM; Lubbers BV; White BJ; Capik SF; KuKanich B; Riviere JE; Tessman RK J Vet Pharmacol Ther; 2016 Apr; 39(2):157-66. PubMed ID: 26441021 [TBL] [Abstract][Full Text] [Related]
15. Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine. Sun D; Mi K; Hao H; Xie S; Chen D; Huang L BMC Vet Res; 2020 Sep; 16(1):366. PubMed ID: 32993661 [TBL] [Abstract][Full Text] [Related]
16. PK-PD Analysis of Marbofloxacin against Lei Z; Liu Q; Yang B; Khaliq H; Cao J; He Q Front Pharmacol; 2017; 8():856. PubMed ID: 29209222 [TBL] [Abstract][Full Text] [Related]
17. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Lepak AJ; Andes DR Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072 [TBL] [Abstract][Full Text] [Related]
18. In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis. Xiao X; Sun J; Chen Y; Huang RJ; Huang T; Qiao GG; Zhou YF; Liu YH BMC Vet Res; 2015 Feb; 11():33. PubMed ID: 25889187 [TBL] [Abstract][Full Text] [Related]
19. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis. Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889 [TBL] [Abstract][Full Text] [Related]
20. How can we predict bacterial eradication? Jacobs MR Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]